ValuEngine upgraded shares of Eyenovia (NASDAQ:EYEN) from a hold rating to a buy rating in a report issued on Thursday, ValuEngine reports.
Several other equities research analysts have also weighed in on EYEN. HC Wainwright set a $14.00 price objective on Eyenovia and gave the stock a buy rating in a research note on Wednesday, June 5th. Oppenheimer assumed coverage on Eyenovia in a research note on Wednesday, April 24th. They set an outperform rating and a $9.00 price objective for the company. Finally, Zacks Investment Research raised Eyenovia from a sell rating to a hold rating in a research note on Tuesday, June 25th.
NASDAQ EYEN traded up $0.07 on Thursday, reaching $3.28. 15,859 shares of the stock traded hands, compared to its average volume of 269,486. The stock’s fifty day moving average price is $3.79. The company has a market capitalization of $52.45 million, a P/E ratio of -1.80 and a beta of 1.12. Eyenovia has a 12 month low of $2.40 and a 12 month high of $6.98.
Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. As a group, research analysts anticipate that Eyenovia will post -1.8 EPS for the current year.
In related news, Director Curt H. Labelle acquired 17,985 shares of Eyenovia stock in a transaction dated Thursday, July 11th. The stock was acquired at an average cost of $2.78 per share, with a total value of $49,998.30. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Tsontcho Ianchulev acquired 233,813 shares of Eyenovia stock in a transaction dated Thursday, July 11th. The shares were bought at an average cost of $2.78 per share, with a total value of $650,000.14. The disclosure for this purchase can be found here. Company insiders own 43.10% of the company’s stock.
An institutional investor recently bought a new position in Eyenovia stock. Bank of New York Mellon Corp bought a new position in Eyenovia Inc (NASDAQ:EYEN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned 0.11% of Eyenovia as of its most recent SEC filing. Institutional investors own 7.88% of the company’s stock.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Featured Article: Calculate Your Return on Investment (ROI)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.